Hansa Biopharma AB

Hansa Biopharma's HNSA-5487 showed rapid IgG reduction by over 95% in NICE-01 trial, with normal IgG levels returning within 6 months. The drug demonstrated lower anti-drug antibody levels and robust IgG reduction efficacy, suggesting potential for redosing and addressing unmet needs in autoimmune diseases like MOGAD, NMO, and MG.

Hansa Biopharma announced positive 12-month follow-up results from the NICE-01 trial of HNSA-5487, showing rapid IgG reduction, normal recovery, and favorable safety profile. HNSA-5487 demonstrated lower immunogenicity and redosing potential compared to imlifidase, with plans to focus clinical development on autoimmune diseases like MOGAD, NMO, and MG.